Literature DB >> 7705164

Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation.

C A Keller1, P T Cagle, R W Brown, G Noon, A E Frost.   

Abstract

Thirty-two recipients of single, double, or heart-lung transplantation followed-up for at least 3 months posttransplant were retrospectively reviewed to assess the frequency, predictors, and risk factors associated with the development of bronchiolitis obliterans (BO). A clinical definition for the diagnosis of BO was made using the following criteria: persistent and progressive decline in FEF25-75, associated with normal results of cytologic and microbiologic studies for significant pathogens in bronchoalveolar lavage fluid, with a normal chest radiograph. This was correlated with histologic diagnosis and patient outcome. Sixteen (50%) of the patients developed BO, and this was associated with a 56% mortality. All but 1 patient with histologic BO had a clinical diagnosis of BO made (often months) prior to diagnostic biopsy. No patients with normal histologic findings had a clinical diagnosis of BO. More than 3 episodes of histologically documented acute rejections in any 12-month period were eventually associated with a 100% incidence of BO. Cytomegalovirus occurred with greater frequency in patients with BO, and in most cases, preceded or occurred concomitantly with the diagnosis of acute rejection or BO.

Entities:  

Mesh:

Year:  1995        PMID: 7705164     DOI: 10.1378/chest.107.4.973

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

Review 1.  Human and murine obliterative bronchiolitis in transplant.

Authors:  John F McDyer
Journal:  Proc Am Thorac Soc       Date:  2007-01

2.  Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome.

Authors:  S S Weigt; R M Elashoff; C Huang; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; M P Keane; R Saggar; J P Lynch; D A Zisman; D J Ross; J A Belperio
Journal:  Am J Transplant       Date:  2009-05-13       Impact factor: 8.086

3.  Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection.

Authors:  Aric L Gregson; Aki Hoji; Rajan Saggar; David J Ross; Bernard M Kubak; Beth D Jamieson; S Samuel Weigt; Joseph P Lynch; Abbas Ardehali; John A Belperio; Otto O Yang
Journal:  Transplantation       Date:  2008-04-15       Impact factor: 4.939

Review 4.  Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies.

Authors:  Andrew I R Scott; Linda D Sharples; Susan Stewart
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Short-course rapamycin treatment preserves airway epithelium and protects against bronchiolitis obliterans.

Authors:  Jacob R Gillen; Yunge Zhao; David A Harris; Damien J LaPar; Irving L Kron; Christine L Lau
Journal:  Ann Thorac Surg       Date:  2013-06-24       Impact factor: 4.330

6.  Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality.

Authors:  Hsuanwen C Huang; S Samuel Weigt; Ariss Derhovanessian; Vyacheslav Palchevskiy; Abbas Ardehali; Rajan Saggar; Rajeev Saggar; Bernard Kubak; Aric Gregson; David J Ross; Joseph P Lynch; Robert Elashoff; John A Belperio
Journal:  J Heart Lung Transplant       Date:  2011-04-08       Impact factor: 10.247

7.  Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker.

Authors:  Damien J LaPar; Marie D Burdick; Abbas Emaminia; David A Harris; Brett A Strieter; Ling Liu; Mark Robbins; Irving L Kron; Robert M Strieter; Christine L Lau
Journal:  Ann Thorac Surg       Date:  2011-08       Impact factor: 4.330

Review 8.  Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation.

Authors:  S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2013-07-02       Impact factor: 3.119

9.  Interstitial pneumonitis and the risk of chronic allograft rejection in lung transplant recipients.

Authors:  Andrew D Mihalek; Ivan O Rosas; Robert F Padera; Anne L Fuhlbrigge; Gary M Hunninghake; Dawn L DeMeo; Phillip C Camp; Hilary J Goldberg
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Usefulness of immune monitoring in lung transplantation using adenosine triphosphate production in activated lymphocytes.

Authors:  Michael Y Shino; S Samuel Weigt; Rajan Saggar; David Elashoff; Ariss Derhovanessian; Aric L Gregson; Rajeev Saggar; Elaine F Reed; Bernard M Kubak; Joseph P Lynch; John A Belperio; Abbas Ardehali; David J Ross
Journal:  J Heart Lung Transplant       Date:  2012-09       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.